"All disease begins in the gut." - Hippocrates
Until recently, there has been little insight into the root cause of metabolic disease and, as a result, advancements to address the resulting conditions have been incremental at best – addressing only symptoms, with little impact on patient outcomes. At Fractyl, we are applying new scientific insights in intestinal biology to advance treatments and potential cures for metabolic diseases.
Our product pipeline leverages our proprietary procedural therapy, which is designed to rejuvenate the lining of the duodenum to improve patient health, and initially targets patients with metabolic conditions resulting from insulin resistance, including type 2 diabetes (T2D), nonalcoholic steatohepatitis (NASH), and polycystic ovarian syndrome (PCOS).
The intestinal lining (duodenal mucosa) is our body’s largest hormone-producing (“endocrine”) organ, the largest nervous system outside of the brain, an important line of defense against infection, and host to a complex microbiome.
Our research has demonstrated that insulin resistance is caused by an overgrowth (hyperplasia) of the duodenal lining that results from years of diets high in fats and sugar. This hyperplasia leads to changes in key hormones produced and key nutrients absorbed in this section of the gut, which not only affects the insulin produced by the pancreas, but also the body’s response to that insulin, leading directly to insulin resistance and metabolic disease.
Poor diet causes overgrowth in the duodenal lining resulting in serious metabolic disease
To restore insulin sensitivity, we have developed, Revita™ DMR (duodenal mucosal resurfacing), a minimally invasive, outpatient procedural therapy designed to rejuvenate the lining of the duodenum and improve patient health.
We have received a CE Mark to commercialize Revita DMR in Europe based on our early clinical work, and global, follow-on clinical trials are advancing in T2D, NASH and PCOS. In addition, we are exploring the use of our Revita DMR technology coupled with cell and gene therapy to fully restore patient health.
The intestinal lining (duodenal mucosa) is our body’s largest hormone-producing (“endocrine”) organ, the largest nervous system outside of the brain, an important line of defense against infection, and host to a complex microbiome.